Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$9.31 +1.7%	$8.28	$2.99 ▼ $10.28	$1.41B	1.75	1.58 million shs	1.75 million shs
INBX Inhibrx	$13.75 +6.5%	$12.41	$10.80 ▼ $18.95	$186.89M	N/A	119,946 shs	140,633 shs
SANA Sana Biotechnology	$2.27 +0.9%	$1.76	$1.26 ▼ $8.17	$511.83M	1.75	3.46 million shs	3.08 million shs
VALN Valneva	$6.40 +0.5%	$6.58	$3.62 ▼ $9.50	$535.27M	1.85	42,313 shs	2,217 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	+1.75%	+5.32%	+22.34%	+12.71%	+160.06%
INBX Inhibrx	+6.51%	+9.65%	+17.32%	+3.77%	-59.69%
SANA Sana Biotechnology	+0.89%	+13.50%	+32.75%	-13.03%	-70.71%
VALN Valneva	+0.47%	+1.11%	-0.78%	-5.19%	-28.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	3.1976 of 5 stars	1.4	2.0	4.2	4.2	2.5	0.6
INBX Inhibrx	2.1091 of 5 stars	0.0	1.0	4.6	3.3	2.5	1.3
SANA Sana Biotechnology	2.3638 of 5 stars	3.4	0.0	0.0	3.3	3.3	0.6
VALN Valneva	2.2634 of 5 stars	3.5	5.0	0.0	1.5	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.83	Moderate Buy	$9.83	5.62% Upside
INBX Inhibrx	2.00	Hold	N/A	N/A
SANA Sana Biotechnology	2.86	Moderate Buy	$10.80	375.77% Upside
VALN Valneva	3.00	Buy	$15.50	142.19% Upside

Current Analyst Ratings Breakdown

Latest ADPT, INBX, VALN, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	INBX Inhibrx	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/8/2025	VALN Valneva	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
5/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00 ➝ $13.00
5/5/2025	ADPT Adaptive Biotechnologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $9.00
5/2/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/15/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/9/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
3/31/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
3/24/2025	VALN Valneva	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $15.00
3/21/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$8.00 ➝ $9.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$189.53M	7.46	N/A	N/A	$1.37 per share	6.80
INBX Inhibrx	$200K	995.23	N/A	N/A	N/A	∞
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.46 per share	N/A
VALN Valneva	$186.06M	2.88	N/A	N/A	$2.00 per share	3.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-89.12%	-64.65%	-26.45%	8/7/2025 (Estimated)
INBX Inhibrx	-$154.96M	$116.75	0.12	N/A	N/A	N/A	-113.74%	-80.56%	6/16/2025 (Estimated)
SANA Sana Biotechnology	-$283.26M	-$0.88	N/A	N/A	N/A	N/A	-84.22%	-44.97%	8/14/2025 (Estimated)
VALN Valneva	-$109.78M	-$1.19	N/A	N/A	N/A	-4.35%	-3.93%	-1.42%	8/12/2025 (Estimated)

Latest ADPT, INBX, VALN, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q4 2024	INBX Inhibrx	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
5/7/2025	Q1 2025	VALN Valneva	-$0.40	-$0.13	+$0.27	-$0.13	$41.80 million	$51.79 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million
3/20/2025	Q4 2024	VALN Valneva	-$0.22	-$0.54	-$0.32	-$0.54	$55.64 million	$56.48 million
3/17/2025	Q4 2024	INBX Inhibrx	-$2.88	-$3.09	-$0.21	-$3.09	N/A	$0.10 million
3/17/2025	Q4 2024	SANA Sana Biotechnology	-$0.25	-$0.23	+$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.89	2.81
INBX Inhibrx	N/A	4.70	4.70
SANA Sana Biotechnology	N/A	4.47	4.47
VALN Valneva	0.70	2.78	2.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
INBX Inhibrx	82.46%
SANA Sana Biotechnology	88.23%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
INBX Inhibrx	17.09%
SANA Sana Biotechnology	30.10%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	138.43 million	Optionable
INBX Inhibrx	166	14.48 million	11.26 million	Optionable
SANA Sana Biotechnology	380	225.48 million	153.83 million	Optionable
VALN Valneva	700	83.64 million	69.15 million	Not Optionable

ADPT, INBX, VALN, and SANA Headlines

Recent News About These Companies

Valneva to Participate at U.S. and European Investor Conferences in June

May 26, 2025 | globenewswire.com

US CDC accepts recommendations for chikungunya vaccines

May 21, 2025 | msn.com

London man among thousands who've rolled up their sleeves to trial Lyme disease vaccine

May 19, 2025 | cbc.ca

US Advises Older Travelers to Avoid Chikungunya Vaccine

May 16, 2025 | infectiousdiseaseadvisor.com

FDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for Seniors

May 15, 2025 | pharmexec.com

FDA, CDC recommend pause in Valneva chikungunya vaccine for older adults

May 14, 2025 | cidrap.umn.edu

U.S. Advises Older Travelers to Avoid Chikungunya Vaccine

May 13, 2025 | usnews.com

FDA warns seniors to avoid this vaccine after deadly complications

May 13, 2025 | msn.com

2VALN : US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For...

May 13, 2025 | benzinga.com

COVID-19 fueled increase in hospital-onset MRSA, study finds

May 12, 2025 | cidrap.umn.edu

FDA, EU Flag Safety Issues With Valneva’s Chikungunya Vaccine

May 12, 2025 | biospace.com

FDA follows EMA in limiting use of Valneva shot

May 12, 2025 | biopharmadive.com

What Is the Chikungunya Vaccine? CDC Issues Notice to Older Travelers

May 12, 2025 | msn.com

US health officials advise older travelers not to get a chikungunya vaccine

May 12, 2025 | apnews.com

Valneva’s chikungunya vaccine use halted in older adults amid safety concerns

May 12, 2025 | finance.yahoo.com

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

May 12, 2025 | globenewswire.com

U.S. recommends a pause in Valneva chikungunya vaccine for those over 60

May 10, 2025 | msn.com

Eli Lilly extends Purdue alliance; EMA investigates Valneva shot

May 10, 2025 | finance.yahoo.com

Valneva SE 2025 Q1 - Results - Earnings Call Presentation

May 8, 2025 | seekingalpha.com

Valneva SE (INRLF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...

May 8, 2025 | finance.yahoo.com

Valneva (NASDAQ:VALN) Sees Unusually-High Trading Volume - Here's What Happened

May 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT, INBX, VALN, and SANA Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$9.31 +0.16 (+1.75%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$9.30 -0.01 (-0.11%)

As of 05/29/2025 05:53 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Inhibrx NASDAQ:INBX

$13.75 +0.84 (+6.51%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$13.69 -0.06 (-0.44%)

As of 05/29/2025 04:37 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Sana Biotechnology NASDAQ:SANA

$2.27 +0.02 (+0.89%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$2.25 -0.02 (-0.88%)

As of 05/29/2025 07:52 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Valneva NASDAQ:VALN

$6.42 +0.05 (+0.86%)

As of 05/29/2025 04:00 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time